Table 4 Description of patients with acute community-acquired Lm meningitis who survivied or died
Survivors n = 31 | Non-Survivors n = 12 | p | |
|---|---|---|---|
Age (median ± IQR) | 67 ± 26 | 71 ± 43 | 0.999 |
Elderly patient | 17 (55) | 7 (58) | 0.836 |
Immunocompromised | 22 (71) | 7 (58) | 0.482 |
Neurological finding | 9 (29) | 2 (17) | 0.698 |
GCSb at presentation (median ± IQR) | 13 ± 11 | 13 ± 8 | 0.453 |
Classic Triadc | 14 (45) | 7 (58) | 0.438 |
WBC > 999 cells/mL | 10 (33) | 5 (42) | 0.282 |
Protein level g/L (median ± IQR) | 2.08 ±1.3 | 2.1 ± 4.4 | 0.685 |
CSFd/blood glucose ratio (median ± IQR) | 0.27 ± 0.24 | 0.18 ± 0.21 | 0.448 |
Hyponatremia | 13 (42) | 6 (50) | 0.633 |
Seizures | 2 (7) | 2 (17) | 0.308 |
Empirical Ampicilllin + gentamicin therapy | 8 (26) | 3 (25) | 0.957 |
Definitive Ampicillin + gentamicin therapy | 10 (32) | 8 (67) | 0.040 |
Dexamethasone concomitant to antibiotic | 17 (55) | 4 (33) | 0.206 |
Phenytoin | 8 (26) | 3 (25) | 0.999 |